Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Total Current Liabilities (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Total Current Liabilities for 14 consecutive years, with $36.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 6.36% year-over-year to $36.1 million, compared with a TTM value of $36.1 million through Dec 2025, down 6.36%, and an annual FY2025 reading of $36.1 million, down 6.36% over the prior year.
  • Total Current Liabilities was $36.1 million for Q4 2025 at Fate Therapeutics, up from $28.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $114.1 million in Q4 2022 and bottomed at $28.1 million in Q3 2025.
  • Average Total Current Liabilities over 5 years is $60.6 million, with a median of $45.0 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities skyrocketed 279.46% in 2021, then plummeted 65.72% in 2023.
  • Year by year, Total Current Liabilities stood at $81.3 million in 2021, then soared by 40.31% to $114.1 million in 2022, then tumbled by 65.72% to $39.1 million in 2023, then dropped by 1.46% to $38.5 million in 2024, then decreased by 6.36% to $36.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for FATE at $36.1 million in Q4 2025, $28.1 million in Q3 2025, and $28.7 million in Q2 2025.